The Terra Innovatum Global N.V. (NASDAQ: NKLR) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures, including current reports, registration statements, and exhibits related to its micro-modular nuclear reactor business. As an emerging growth company incorporated in the Netherlands and listed on The Nasdaq Stock Market LLC, Terra Innovatum files documents with the U.S. Securities and Exchange Commission that describe its corporate structure, risk factors, business combination history, and progress as a developer of the SOLO™ Micro-Modular Reactor.
Among these filings, investors can review current reports on Form 8‑K, such as disclosures about letters of intent with customers, business combination milestones, and other material events. For example, a Form 8‑K identifies Terra Innovatum Global N.V. as the registrant, confirms its Nasdaq ticker symbol NKLR, and references a press release regarding the execution of a letter of intent with a customer. Over time, the company’s quarterly and annual reports (Forms 10‑Q and 10‑K, when filed) are expected to provide more detailed information on its financial position, regulatory strategy with the U.S. Nuclear Regulatory Commission, and the status of its SOLO reactor development and commercialization plans.
On Stock Titan, these filings are complemented by AI-powered summaries designed to help readers interpret key points in lengthy documents. Users can quickly see the main topics of a filing, such as updates on NRC engagement, manufacturing agreements with partners like ATB Riva Calzoni, or changes in capital structure following a business combination. The platform also surfaces insider transaction reports on Form 4, proxy materials on executive and board matters when available, and other SEC forms that contribute to a fuller picture of NKLR’s regulatory and corporate history.
By combining real-time EDGAR updates with concise AI explanations, this page helps investors, analysts, and researchers navigate Terra Innovatum’s SEC filings and understand how its disclosures relate to the development of the SOLO micro-modular reactor.
Terra Innovatum Global N.V. (NKLR) supplements its prospectus covering up to 5,475,593 ordinary shares issuable upon warrant exercise, up to 94,804,436 ordinary shares, and up to 40,200,000 ordinary shares issuable upon mandatory conversion of outstanding preferred shares. The supplement attaches two current reports concerning the company’s independent auditor transition.
The audit committee dismissed KPMG effective October 12, 2026, and MaloneBailey was formally engaged on October 23 as independent auditor for the fiscal year ending December 31, 2026. Terra Innovatum reported no disagreements with KPMG and no reportable events other than previously disclosed material weaknesses in internal control over financial reporting, which remain unremediated. KPMG’s 2025 audit report was not adverse or disclaimed and was not qualified or modified as to uncertainty, audit scope, or accounting principles.
Terra Innovatum Global N.V. engaged MaloneBailey, LLP as its independent registered public accounting firm for the fiscal year ending December 31, 2026. MaloneBailey previously served in that role from April 29, 2025, to January 15, 2026.
Terra Innovatum Global N.V. (NKLR) seeks shareholder votes at its November 16, 2026 annual meeting on 2025 accounts matters, director appointments, director equity awards, a revised remuneration policy, a share-buyback authorization and withdrawal of KPMG’s Dutch audit engagement for 2025. The Board recommends voting “FOR” each voting item.
Proposed director awards are capped at 2,000,000 ordinary shares or rights to acquire ordinary shares for November 16, 2026 through December 31, 2029, with annual increases of up to 250,000; approval would not expand the existing plan reserve. The proposed policy sets executive short-term incentives at a 100%-of-base-salary target, with maximums of 100% of base salary if cash-settled or up to 250% if equity-settled, and permits a future long-term plan subject to approvals. The proposed 18-month buyback is limited to 10% of issued capital and a price no higher than 110% of the average closing price on the five trading days preceding agreement; the company says it does not currently intend to exercise the authorization.
KPMG’s appointment as independent registered public accounting firm ended October 12, 2026, and MaloneBailey was engaged October 23 for 2026. Terra Innovatum says it qualifies as a small legal entity, so its Dutch statutory audit for 2025 is not required. Internal-control material weaknesses remain unremediated; MaloneBailey’s report for the period ended April 29, 2025 expressed substantial doubt about the company’s ability to continue as a going concern.
Terra Innovatum Global N.V. (NKLR) asks shareholders to vote at its November 16, 2026 annual meeting on 2025 accounts, director appointments and compensation, a revised pay policy, a share-repurchase authorization and withdrawal of KPMG Accountants N.V.’s Dutch audit engagement for 2025. The Board recommends “FOR” all voting proposals.
The proposed director award limit is 2,000,000 ordinary shares or rights through December 31, 2029, with annual increases of up to 250,000; approval would not increase the Equity Incentive Plan’s available share reserve. Proposed executive short-term incentives target 100% of base salary, with a maximum of 100% if paid in cash or up to 250% if settled in equity. The proposed repurchase mandate would last 18 months, cap purchases at 10% of issued capital and price at 110% of the preceding five-trading-day average; the company says it does not currently intend to use it.
The company says it qualifies as a small legal entity and is exempt from the 2025 statutory Dutch audit, so withdrawal of that engagement is proposed. Separately, the Audit Committee dismissed KPMG as independent registered public accounting firm on October 12, 2026, and approved a MaloneBailey engagement subject to standard client acceptance procedures. Disclosed internal-control material weaknesses remain unremediated; MaloneBailey’s April 29, 2025 report expressed substantial doubt about going concern.
Terra Innovatum Global N.V. (NKLR) dismissed KPMG Accountants N.V. as its independent registered public accounting firm, effective October 12, 2026. The Audit Committee approved MaloneBailey, LLP for the fiscal year ending December 31, 2026, and the company intends to engage the firm subject to completion of its standard client acceptance procedures.
The company said the change was not due to a disagreement with KPMG. KPMG’s report on the 2025 financial statements was not adverse, disclaimed, qualified, or modified as to uncertainty, audit scope, or accounting principles. Material weaknesses in internal control over financial reporting remain unremediated. MaloneBailey previously served as auditor from April 29, 2025, to January 15, 2026.
Terra Innovatum Global N.V. (NKLR) supplements a prospectus whose cover identifies up to 94,804,436 ordinary shares. The cover also lists up to 5,475,593 ordinary shares issuable upon warrant exercise and up to 40,200,000 ordinary shares issuable upon mandatory conversion of outstanding preferred shares.
Cesare Frepoli resigned from the board effective October 2, 2026, solely to ensure the board remained majority independent as required by Nasdaq Listing Rule 5605(b). He remains the company’s Chief Operating Officer and Co-Chief Executive Officer of its U.S. subsidiary.
Terra Innovatum Global N.V. (NKLR) said Cesare Frepoli notified the company on October 2, 2026, of his intention to resign as a director, effective that day. Frepoli will remain the company’s Chief Operating Officer and Co-Chief Executive Officer of its U.S. subsidiary. The company said the resignation is solely to ensure the Board remains majority independent as required by NASDAQ Listing Rule 5605(b).
Terra Innovatum Global N.V.’s prospectus cover lists up to 94,804,436 ordinary shares, up to 5,475,593 ordinary shares issuable upon warrant exercise, and up to 40,200,000 ordinary shares issuable upon mandatory conversion of outstanding preferred shares. The September 22, 2026 supplement adds a current report on board changes.
Rex Jackson and Michael Howard resigned as directors effective September 17, 2026; Peter Hastings also resigned that day and agreed to transition to a consulting role expected to support commercialization efforts and related strategic initiatives. On September 22, 2026, Tony Tullio, Michael Modro and Kostadin Ivanov were appointed independent directors. Tullio also became interim Audit Committee chair and a Remuneration Committee member.
Terra Innovatum Global N.V. disclosed three board departures effective September 17, 2026: Rex Jackson and Michael Howard resigned, and Peter Hastings resigned after agreeing to transition to a consulting role. Hastings is expected to support the company’s ongoing commercialization efforts and related strategic initiatives.
On September 22, 2026, Tony Tullio, Michael Modro and Kostadin Ivanov were appointed independent directors. Tullio was also appointed interim chairman of the Board’s Audit Committee and a member of its Remuneration Committee. The departing and incoming directors are expected to enter into indemnification agreements substantially consistent with the filed form.
Terra Innovatum Global N.V. (NKLR) filed a prospectus supplement to its Form S-1 registering up to 5,475,593 Ordinary Shares issuable upon exercise of warrants, up to 94,804,436 Ordinary Shares, and up to 40,200,000 Ordinary Shares issuable upon mandatory conversion of outstanding preferred shares. On August 14, 2026, its Ordinary Shares closed at $6.09 on Nasdaq.
The attached current report describes the appointment of Katherine Williams as Chief Financial Officer of the U.S. subsidiary and as an executive director/CFO of Terra Innovatum Global N.V. Her package includes a base salary of $465,000, a one-time $40,000 sign-on bonus, and an annual performance-based MBO bonus opportunity between 50% and 250% of base salary, plus severance and change-in-control protections providing up to 18 months of salary, target bonus, 18 months of healthcare coverage, equity-vesting acceleration, and up to $30,000 of outplacement services in certain termination scenarios.